42 related articles for article (PubMed ID: 35301639)
1. Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study.
Wang S; Wang Y; Zhu C; Liu K; Chao J; Zhang N; Piao M; Yang X; Zhang L; Long J; Xun Z; Zhang T; Sang X; Yang X; Zhao H
Int J Surg; 2024 May; ():. PubMed ID: 38704621
[TBL] [Abstract][Full Text] [Related]
2. Editorial: Meningioma: From basic research to clinical translational study, volume II.
Tang H; Shen Z; Eisenstat DD; Dunn IF
Front Oncol; 2023; 13():1150514. PubMed ID: 37051539
[No Abstract] [Full Text] [Related]
3. The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis.
Gregory GE; Islim AI; Hannan CJ; Jones AP; Hammerbeck-Ward C; Rutherford SA; Freeman SR; Lloyd S; Kalamarides M; Smith MJ; Couper K; McBain CA; Jenkinson MD; Brough D; King AT; Evans DG; Pathmanaban ON
Neurooncol Adv; 2023 May; 5(Suppl 1):i94-i104. PubMed ID: 37287576
[TBL] [Abstract][Full Text] [Related]
4. The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review.
Shahbandi A; Shah DS; Hadley CC; Patel AJ
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672431
[TBL] [Abstract][Full Text] [Related]
5. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic
Brastianos PK; Twohy EL; Gerstner ER; Kaufmann TJ; Iafrate AJ; Lennerz J; Jeyapalan S; Piccioni DE; Monga V; Fadul CE; Schiff D; Taylor JW; Chowdhary SA; Bettegowda C; Ansstas G; De La Fuente M; Anderson MD; Shonka N; Damek D; Carrillo J; Kunschner-Ronan LJ; Chaudhary R; Jaeckle KA; Senecal FM; Kaley T; Morrison T; Thomas AA; Welch MR; Iwamoto F; Cachia D; Cohen AL; Vora S; Knopp M; Dunn IF; Kumthekar P; Sarkaria J; Geyer S; Carrero XW; Martinez-Lage M; Cahill DP; Brown PD; Giannini C; Santagata S; Barker FG; Galanis E
J Clin Oncol; 2023 Jan; 41(3):618-628. PubMed ID: 36288512
[TBL] [Abstract][Full Text] [Related]
6. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.
Kumthekar P; Grimm SA; Aleman RT; Chamberlain MC; Schiff D; Wen PY; Iwamoto FM; Gursel DB; Reardon DA; Purow B; Kocherginski M; Helenowski I; Raizer JJ
Neurooncol Adv; 2022; 4(1):vdac123. PubMed ID: 36225651
[TBL] [Abstract][Full Text] [Related]
7. Emerging systemic treatment options in meningioma.
Mair MJ; Berghoff AS; Brastianos PK; Preusser M
J Neurooncol; 2023 Jan; 161(2):245-258. PubMed ID: 36181606
[TBL] [Abstract][Full Text] [Related]
8. Volumetric growth rate of incidentally found meningiomas on immunotherapy.
Berger A; Mullen R; Bernstein K; Mashiach E; Meng Y; Silverman JS; Sulman EP; Golfinos JG; Kondziolka D
J Neurooncol; 2024 Jan; 166(2):303-307. PubMed ID: 38194196
[TBL] [Abstract][Full Text] [Related]
9. The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors.
Alimonti P; Gonzalez Castro LN
Antibodies (Basel); 2023 Apr; 12(2):. PubMed ID: 37092448
[TBL] [Abstract][Full Text] [Related]
10. Novel Human Meningioma Organoids Recapitulate the Aggressiveness of the Initiating Cell Subpopulations Identified by ScRNA-Seq.
Huang M; Xu S; Li Y; Shang L; Zhan X; Qin C; Su J; Zhao Z; He Y; Qin L; Zhao W; Long W; Liu Q
Adv Sci (Weinh); 2023 May; 10(15):e2205525. PubMed ID: 36994665
[TBL] [Abstract][Full Text] [Related]
11. The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches.
Kalluri AL; Shah PP; Lim M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768342
[TBL] [Abstract][Full Text] [Related]
12. A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors.
Lehrer EJ; Jones BM; Sindhu KK; Dickstein DR; Cohen M; Lazarev S; Quiñones-Hinojosa A; Green S; Trifiletti DM
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428546
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review.
Nidamanuri P; Drappatz J
J Neurooncol; 2022 Apr; 157(2):271-276. PubMed ID: 35301639
[TBL] [Abstract][Full Text] [Related]
14. Systemic and local immunosuppression in patients with high-grade meningiomas.
Li YD; Veliceasa D; Lamano JB; Lamano JB; Kaur G; Biyashev D; Horbinski CM; Kruser TJ; Bloch O
Cancer Immunol Immunother; 2019 Jun; 68(6):999-1009. PubMed ID: 31030234
[TBL] [Abstract][Full Text] [Related]
15. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.
Bi WL; Nayak L; Meredith DM; Driver J; Du Z; Hoffman S; Li Y; Lee EQ; Beroukhim R; Rinne M; McFaline-Figueroa R; Chukwueke U; McCluskey C; Gaffey S; Cherniack AD; Stefanik J; Doherty L; Taubert C; Cifrino M; LaFrankie D; Graillon T; Wen PY; Ligon KL; Al-Mefty O; Huang RY; Muzikansky A; Chiocca EA; Santagata S; Dunn IF; Reardon DA
Neuro Oncol; 2022 Jan; 24(1):101-113. PubMed ID: 34015129
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
